LA JOLLA, Calif., Oct. 27 /PRNewswire/ -- Unexpected drug toxicities & restricted patient responses have resulted in a re-examination of the process of preclinical development in drug discovery. This has led to a variety of novel methods that may minimize compound toxicity or define the patient population entering clinical trials. An inaugural event entitled "New Trends & Technologies Accelerating Preclinical Development" will review a number of aspects in preclinical development -- which will convene on January 24-25, 2005 in San Diego, announces Strategic Research Institute.
This conference will consist of a well-distinguished faculty coming from industry/academia who will reveal their latest strategies to optimize target identification, lead identification, ADME/Tox and the use of animal models & biomarkers. An afternoon forum on "Translating Science to Business" and "R&D Productivity" is also featured on the agenda, thus provoking the audience to think about what challenges lie ahead and where the industry needs to be heading in the future.
Highlights of this event will include the Keynote Addresses "Mouse Model Research for Preclinical Development" to be given by Richard P. Woychik, Ph.D., Director, The Jackson Laboratory & "Predicting Drug Disposition" to be given by Leslie Z. Benet, Ph.D., Professor in Biopharmaceutical Sciences, University of California San Francisco.
Complete list of presenters include: Abbott Laboratories, Biogen Idec, Caprion Pharmaceuticals Inc., DiscoveRx, GVK Biosciences, Iconix Pharmaceuticals, Isis Pharmaceuticals, Merck Research Laboratories, Mouse Specifics Inc., Novartis Pharmaceuticals, Pfizer Global R&D La Jolla, Pfizer Inc., Phylonix Pharmaceuticals, Recombinant Capital, Simulations-Plus Inc., Vitra Bioscience Inc., Xceleron Ltd., National Cancer Institute, National Institutes of Health, The Jackson Laboratory, University of California San Francisco, University of Pennsylvania Medical Center and University of Toronto.
Scientific Advisory Board:
- Zahra Parandoosh, Pharm.D., Ph.D., Managing Director, ChemCyte
- Rakesh Dixit, Ph.D., DABT, Section Head, Toxicokinetics and Biomarkers
Dept., Merck Research Laboratories
- Richard M. Eglen, Chief Scientific Officer, DiscoveRx
- Wick Johnson, Ph.D., Director, Licensing & Development, Pfizer Inc.
- Peter F. Smith, Ph.D., Senior VP, Preclinical Drug Development,
To view the agenda and/or register online please go to http://www.srinstitute.com/cs322.
To receive the full agenda and/or register for the conference, please contact Ed Drilon of Strategic Research Institute at firstname.lastname@example.org or 212-967-0095, x233 (please include name, corporate affiliation, mailing address, and fax number and specify what you are interested in).
For more information on sponsorship & exhibition opportunities, please contact Rita Karsadi at email@example.com or at 480-634-8986.
To inquire about becoming a media partner please contact Cheryl Kahan- Radhuber at firstname.lastname@example.org.
Strategic Research Institute L.P.